Company intelligence / Profile preview

Biosantech

Sophia Antipolis, Provence-Alpes-Cote d'Azur, France

Ownership: Private
Development stage: Phase 2

Overview

Biosantech is a private French biopharmaceutical company focused on developing a therapeutic HIV vaccine. The company is best known for Tat Oyi, a synthetic protein vaccine candidate designed to target the HIV Tat protein and potentially control viral rebound in people living with HIV after treatment interruption. Biosantech has sponsored a Phase I/II clinical study of this candidate in seropositive patients and has presented results suggesting immunogenicity and an effect on viral rebound. The company appears to be a small, single-asset biotech centered on HIV/AIDS research rather than a diversified platform business.

Therapeutic areas: Infectious Diseases
Modalities: VaccineProtein
Industry: Biotech

Drug pipeline

1 asset

tat oyi

Beyond the preview

Go deeper on Biosantech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosantech.

Explore the full profile